Neurol. praxi. 2021;22(2):104-112 | DOI: 10.36290/neu.2020.119

Orphan drugs in treatment of rare neuromuscular disorders

doc. MUDr. Peter Špalek, PhD.
Národné expertízne centrum pre zriedkavé neuromuskulárne ochorenia, Neurologická klinika SZU a UNB, Nemocnica Ružinov, Bratislava

Rare disorders (RD) are a group of heterogeneous disorders in relation to their etiology, severity and geographical occurrence. RD are defined by the limit of their maximal prevalence in population, which has been fixed in Europe by 5 persons out of 10 000 inhabitants. Inherited and autoimmune neuromuscular disorders (NMD) belong to largest groups of RD. Current options of immunotherapy significantly improved the prognosis of rare autoimmune NMD. In myasthenia gravis at certain situations (refractory MG; treatment side effects) some new treatment options are available - complement inhibitors (eculizumab), B-cell directed therapy (rituximab) and neonatal Fc receptor antagonists (efgartigimod). New treatments improved significantly the prognosis of some inherited NMD which had in past unfavourable, mostly fatal, prognosis. Spinal muscular atrophy - nusinersen (antisense nucleotid), onasemnogene abeparvovec (gene therapy), risdiplam (splicing modifier). Hereditary amyloid transthyretin polyneuropathy - tafamidis (transthyretin stabilizer), patisiran (small interfering RNAs) and inotersen (antisense oligonucletide) resulting in gene silencing. Fabry disease - agalsidase alfa, agalsidase beta (enzyme replacement therapy), migalastat (chaperone). Lambert-Eaton myasthenic syndrome - amifampridine (blocker of presynaptic potassium channels). Duchenne muscular dystrophy - ataluren (promotes ribosomal readthrough for patients with nonsense DMD mutations), eteplirsen and golodirsen (exon skipping). Pompe disease - recombinant human alfa-glucosidase (enzyme replacement therapy). Malignant hyperthermia - dantrolene (RYR1 receptor blocker). In some rare NMD it will be important to identify biomarkers for tailoring and monitoring therapy in optimizing patient care, including differentiation of treatment responders and non-responders.

Keywords: rare hereditary and autoimmune NMD, orphan drugs, biomarkers.

Received: November 3, 2020; Revised: November 3, 2020; Accepted: November 18, 2020; Prepublished online: November 18, 2020; Published: April 30, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Špalek P. Orphan drugs in treatment of rare neuromuscular disorders. Neurol. praxi. 2021;22(2):104-112. doi: 10.36290/neu.2020.119.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aartsma-Rus A, Krieg AM. FDAApproves Eteplirsen for Duchenne Msucular Dystrophy: The Next Chapter in th Eteplirsen Saga. Nucl Acid Therap 2017; 27: 1-3. Go to original source... Go to PubMed...
    2. Adams D, Suhr OB, Hund D, Obici L, Tournev I, Campistol JM, et al. from the European Network for TTR-FAP (ATTRreuNET): First European consensus for diagnosis, management, and tretment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol 2016; 29 (Suppl. 1): S14-S26. Go to original source... Go to PubMed...
    3. Adams D, Suhr OB, Dyck PJ, Litchy WJ, Leahy RG, Chen J et al. Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary amyloidosis with polyneuropathy. BMC Neurol 2017; 17: 181-193.4. Go to original source... Go to PubMed...
    4. Adams D, Gonzalez-Duarte A, O´Riordan WD, Yang Ch, Ueda M, Kristen AV, Tournev I, et al. Patisiran, an RNAi Therapeutic, for Hereditary Trannsthyretin Amyloidosis. N Engl J Med 2018; 379: 11-21. Go to original source... Go to PubMed...
    5. Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek, Hughes DA, et al. Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 2014; 37: 945-952. Go to original source... Go to PubMed...
    6. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda SI, Lewis WD, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013; 8: 31. Cloi.10.1186/1750-1172-8-31.7. Go to original source... Go to PubMed...
    7. Bednařík J. Lambertův-Eatonův myastenický syndróm. In: Myasthenia gravis. Piťha J, a kol. (eds.). Praha: Maxdorf 2010: s. 284-291.
    8. Benson MD,Waddington-Cruz M, Berk JL, Polydefkis M, Dyck MD, Wang AK et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med 2018; 379: 22-31. Go to original source... Go to PubMed...
    9. Bersano A, Lanfranconi S, Valcarenghi C, Bresolin N, Micieli G, Baron P. Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy. Acta Neurol Scand 2012; 126: 77-97. Go to original source... Go to PubMed...
    10. Bushby K, Finkel R, Wong B, Barohn R, Campbell G, Comi GP, et al. PTC124-GD-007-DMD STUDY GROUP. Ataluren treatment of patients with nonsense mutatiom dystrophinopathy. Muscle Nerve 2014; 50 (4): 477-487. Go to original source... Go to PubMed...
    11. Charleston JS, Schnell FJ, Dworzak J, Donoghue C, Lewis S, Chen L, et al. Eteplirsen treatment for Duchenne Muscular dystrophy: exon skipping and dystrophin production. Neurology 2018; 90: 2146-2154. Go to original source... Go to PubMed...
    12. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Lozeron P, et al. Tafamidis for transthyretin familial amyloid polyneuropathy - a randomized, controlled trial. Neurology 2012; 79: 785-792. Go to original source... Go to PubMed...
    13. Conceicao I, González-Duarte A, Obici L, Schmidt HHJ, Simoneau D, Ong ML, Amass L. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy. J Periph Nerv Syst 2016; 21: 5-9. Go to original source... Go to PubMed...
    14. Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 2012; 45: 319-333. Go to original source... Go to PubMed...
    15. Echaniz-Laguna A, Carlier RY, Laloui K, Carlier P, Salort-Campana E, Pouget J, et al. Should patients with asymptomatic Pompe disease be treated? A nationwide study in France. Muscle Nerve 2015; 51: 884-889. Go to original source... Go to PubMed...
    16. European Medicines Agency [online]. UK. Assessment report: information Spinraza 2017, Apr 21.
    17. Dangouloff T, Burghes A, Tizzano EF, Servais L. SMA Study Group. 244th ENMC international workshop: newborn screening in spinal muscular atrophy May 1-12, 2019, Hoofdorp, Netherlands. Neuromuscul Disord 2020; 30 (1): 93-103. Go to original source... Go to PubMed...
    18. FDA grants accelerated approval to first target treatment for rare Duchenne muscular dystrophy mutation. FDA News Release Dec 12, 2019.
    19. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 2017; 377: 1723-1732. Go to original source... Go to PubMed...
    20. Finsterer J, Iglseder S, Wanschitz J, Topakian R, Löscher WN, Grisold W. Hereditary transthyretin-related amyloidosis. Acta Neurol Scand 2019; 139: 92-105. Go to original source... Go to PubMed...
    21. Gertz MA, Mauermann ML, Grogan M, Coelho T. Advances in the treatment of hereditary transthyretin amyloidosis: A review. Brain Behavior 2019; 00: e01371. DOI: org/10.1002/ brb3.1371. Go to original source... Go to PubMed...
    22. Gidari T, Servais L. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol. 2018 Sept 17; DOI: 10.1111/dmcn.14027 [Epub ahead of print]. Go to original source... Go to PubMed...
    23. Halsall PJ, Robinson RL. Malignant hyperthermia and associated conditions. In: Handbook Clin Neurol, Vol. 86 (3rd series). Myopathies. (eds.). Mastaglia FL, Hilton-Jones D. Malignant hyperthermia and associated conditions. Amsterdam: Elsevier 2007: 107-124. Go to original source...
    24. Hopkin RJ, Jefferies JL, Laney DA, Lawson VH, Mauer M, Taylor MR, Wilcox WR, Fabry Pediatric Expert Panel. The Management and Treatment of Children With Fabry Disease: A United States-based Perspective. Mol Genet Metab 2016; 117: 104-113. Go to original source... Go to PubMed...
    25. Huyard C. How did uncommon disorders become 'rare diseases'? History of a boundary object. Sociol Health Illn. 2009; 31(4): 463-77. DOI: 10.1111/j.1467-9566.2008.01143.x. Go to original source... Go to PubMed...
    26. Chandoga J. Genetické a biochemické aspekty patogenézy transtyretínovej amyloidózy. Neurológia 2020; 15: 5-14.
    27. Juříková L, Danhofer P, Aulická Š. Léčba Duchennovy svalové dystrofie. Neurológia 2020; 15: 31-33.
    28. Kapoor M, Rossor AM, Laura M, Reilly MM. Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis. J Neuromusc Dis 2019; 6: 189-199. Go to original source... Go to PubMed...
    29. Katzin LW, Amato AA. Pompe disease: a review of the current diagnosis and treatment recommendation in the era of enzyme replacement therapy. J Clin Neuromuscul Dis 2008; 9: 421-431. Go to original source... Go to PubMed...
    30. Kariywasam D, Carey KA, Jones KJ, Farrar MA. New and developing therapies in spinal muscular atrophy. Paediatr Resp Rev. 2018; https:doi.org/10.1016/j.prrv.2018.03.003.
    31. Lefebre S, Bűrglen L, Reboullet S, Clermons O, Burlet P, Viollet L, et al. Identification and characterization of spinal muscular atrophy - determining gene. Cell 1995; 80: 155-165. Go to original source... Go to PubMed...
    32. Löscher WN, Humer M, Stulnig TM, Simschitz P, Iglseder S, Eggers C, et al. Pompe disease in Austria: clinical, genetic and epidemiological aspects. J Neurol 2018; 265: 159-164. Go to original source... Go to PubMed...
    33. Kirschner J, Butoianu N, Goemans N, Haberlova J, Koster-Pruszcyk A, Mercuri E, et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur J Paediatr Neurol 2020 Jul 9; DOI: 10.1016/j.ejpn.2020.07.001 [Epub ahead of print]. Go to original source... Go to PubMed...
    34. Mailman MD, Heinz JW, Papp AC. Snyder PJ, Sedra MS, Wirth B, et al. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 2002; 4: 20-26. Go to original source... Go to PubMed...
    35. Mantegazza R, Meisel A, Sieb JP, Le Masson G, Desnuelle C, Essing M. The European LEMS Registry: Baseline Demographics and Treatment Approaches. Neurol Ther 2015; 4: 105-124. Go to original source... Go to PubMed...
    36. Mattosova S, Hlavata A, Spalek P, Kotysova L, Macekova D, Chandoga J. Late-onset form of Pompe disease. Bratisl Med J. 2015; 115: 502-505. Go to original source... Go to PubMed...
    37. Mayberry J, Hobson-Webb LD, Gable KL. Transthyretin familial amyloid polyneuropathy. Early detection can lead to earlier interventions that can slow disease progression significantly. Pract Neurol 2020: 33-41.
    38. McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390: 1489-1498. Go to original source... Go to PubMed...
    39. Mercuri E, Quinlivan R, Tuffery-Giroud S. Early diagnosis and treatment - the use of Ataluren in the effective management of Duchenne muscular dystrophy. Eur Neurol Review 2018; 13: 31-37. Go to original source...
    40. Muntoni F, Desguerre I, Guglieri M, Osorio AN, Kirschner J, Tulinius M, et al. Ataluren use in patients with nonsense mutation Duchenne muscular dystrophy: patients demographics and characteristics from the STRIDE Registry. J Comp Eff Res 2019; 8(14): 1187-1200. Go to original source... Go to PubMed...
    41. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y, Rath A. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020; 28(2): 165-173. DOI: 10.1038/s41431-019-0508-0. Go to original source... Go to PubMed...
    42. Oh SJ, Shcherbakova H, Kostera-Pruszcyk A, Alsharabati M, Schoser B, Sivakumar K, So Y, LEMS Study Group. Amifampridine phosphate (Firdapse) is effective and safe in a phase 3 clinical trial in LEMS. Muscle Nerve 2016; 53: 717-725. Go to original source... Go to PubMed...
    43. Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab 2018; 123: 416-427. Go to original source... Go to PubMed...
    44. Paul-Plether K, Yamamoto T, Bhat MB, Ma J, Ikemoto N, Jimenez LS, Morimoto H. Identification of dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem 2002; 277: 34918-34923. Go to original source... Go to PubMed...
    45. Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, et al. Safety, tolerability pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment naive and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicentre, multinational, ascending dose study. Neuromusc Disord 2019; 29: 167-189. Go to original source... Go to PubMed...
    46. Petrovič R, Fischerová M, Chandoga J. Duchennova muskulárne dystrofia - diagnostika a štruktúra molekulárno-genetických patológií na Slovensku. Neurológia 2020; 15: 25-28.
    47. Rai W, Elsheikh B. Spinal Muscular Atrophy. A devastating disease now has 2 approved breakthrough treatments available. Pract Neurol 2019; 16: 61-65.
    48. Ramdas S, Servais L. New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother 2020; 21: 307-315. Go to original source... Go to PubMed...
    49. Reková P, Sedláková K, Dostálová G, Linhart A. Fabryho choroba, přehled problematiky a nejčastější neurologické projevy. Cesk Slov Neurol N. 2018; 81/114(2): 156-163. Go to original source...
    50. Schneiderbanger D, Johannsen S, Roewer N, Schuster F. Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk Manag 2014; 10: 355-362. Go to original source... Go to PubMed...
    51. Servais L, Kirschner J, Muntoni F. Editorial: Randomisation versus prioritisation in managed Access programe: Lessons from spinal muscular dystrophy. Neuromuscular Dis 2020; 30: 267-269. Go to original source... Go to PubMed...
    52. Schoser B, Stewart A, Kanters S, Mamed A, Jansen J, Chan K, et al. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systemic review and meta-analysis. J Neurol 2017; 264: 621-630. Go to original source... Go to PubMed...
    53. Suhr OB, Ericzon BG. Selection of hereditary transthyretin amyloid patients for liver transplantation: the Swedish experience. Amyloid 2012; 19(Suppl 1): 78-80. Go to original source... Go to PubMed...
    54. SUNFISH - Study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of risdiplam (RO7034067) iny type 2 and 3 spinal muscular atrophy (SMA) participants U.S. National Library of Medicine. Clinical Trials.gov. Identifier: NCT02908685. Last Update Posted: July 22, 2020.
    55. Špalek P. Pompeho choroba (glykogenóza II. typu) - patogenéza, klinický obraz a aktuálne trendy v diagnostike a liečbe. Neurológia 2013; 8: 153-159.
    56. Špalek P. Familiárna amyloidná polyneuropatia. Neurol. praxi 2013; 14: 296-300.
    57. Špalek P. Rabdomyolýza - etiológia, patogenéza, klinický obraz, diagnostika a liečba. Neurológia 2017; 12: 5-10.
    58. Špalek P. Projekt vyhľadávania pacientov s Pompeho a Fabryho chorobou v SR. Neurol. praxi 2017; 18: 374.
    59. Špalek P, Martinka I, Mattošová S, Veverka J, Chandoga J. Prvý prípad sporadickej late-onset formy transtyretínovej familiárnej amyloidnej polyneuropatie v SR. Neurol. praxi 2019; 20: 304-310.
    60. Špalek P, Cibulčík F, Vincent A. Amifampridín - "orphan drug" v liečbe Lambert-Eatonovho myastenického syndrómu: výsledky 4-ročnej liečby u 2 pacientok. Neurológia 2019; 14: 5-11.
    61. Špalek P. Hereditárna amyloidná transtyretínová polyneuropatia: klinické formy, diagnostika a liečba. Neurológia 2020; 15: 17-23.
    62. Tanislav C, Kaps M, Rolfs A, Böttcher T, Lackner K, Paschke E, Mascher H, Laue M, Blaes F. Frequency of Fabry disease in patients with small-fibre neuropathy of unknown aetiology: a pilot study. Eur J Neurol. 2011; 18: 631-636. Go to original source... Go to PubMed...
    63. Tchan M, Henderson R, Kornberg A, Kairaitis K, Fuller M, Davis M, et al. Is it Pompe Disease? Australian diagnostic considerations. Neuromuscular Disorders 2020; 30: 389-399. Go to original source... Go to PubMed...
    64. Ueda M, Yamashita T, Misumi Y, Masuda T, Ando Y. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan. Amyloid 2018; 25: 143-147. Go to original source... Go to PubMed...
    65. Voháňka S. Adultní forma Pompeho nemoci. Cesk Slov Neurol N. 2014; 77/110: 667-676. Go to original source...
    66. Waddington Cruz M, Amass L, Keohane D, Schwartz J, Li H, Gundapaneni B. Early intervention with tafamidis provides long-term (5,5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy. Amyloid 2016; 23: 178-183. Go to original source... Go to PubMed...
    67. Ziegler A, Wilichowski E, Schara U, Hahn A, Műller-Felber W, Johannsen J, et al. Handlungsempfhelungen zur Gentherapie der spinalen Muskelatrophie mit Onasemnogene Abeparvovec AVXS-101. Nervenarzt 2020; 91: 518-529. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.